chr3-81646466-C-G

Variant summary

Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong

The NM_000158.4(GBE1):​c.708G>C​(p.Gln236His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000219 in 1,598,264 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Q236Q) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000021 ( 0 hom. )

Consequence

GBE1
NM_000158.4 missense

Scores

12
4
3

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:10

Conservation

PhyloP100: 0.613

Publications

4 publications found
Variant links:
Genes affected
GBE1 (HGNC:4180): (1,4-alpha-glucan branching enzyme 1) The protein encoded by this gene is a glycogen branching enzyme that catalyzes the transfer of alpha-1,4-linked glucosyl units from the outer end of a glycogen chain to an alpha-1,6 position on the same or a neighboring glycogen chain. Branching of the chains is essential to increase the solubility of the glycogen molecule and, consequently, in reducing the osmotic pressure within cells. Highest level of this enzyme are found in liver and muscle. Mutations in this gene are associated with glycogen storage disease IV (also known as Andersen's disease). [provided by RefSeq, Jul 2008]
GBE1 Gene-Disease associations (from GenCC):
  • glycogen storage disease due to glycogen branching enzyme deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Laboratory for Molecular Medicine, Ambry Genetics, G2P, ClinGen
  • adult polyglucosan body disease
    Inheritance: AR Classification: MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 16 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 5 uncertain in NM_000158.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.949
PP5
Variant 3-81646466-C-G is Pathogenic according to our data. Variant chr3-81646466-C-G is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 2790.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GBE1NM_000158.4 linkc.708G>C p.Gln236His missense_variant Exon 6 of 16 ENST00000429644.7 NP_000149.4 Q04446Q59ET0
GBE1XR_007095662.1 linkn.836G>C non_coding_transcript_exon_variant Exon 6 of 15

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GBE1ENST00000429644.7 linkc.708G>C p.Gln236His missense_variant Exon 6 of 16 1 NM_000158.4 ENSP00000410833.2 Q04446
GBE1ENST00000489715.1 linkc.585G>C p.Gln195His missense_variant Exon 6 of 16 2 ENSP00000419638.1 E9PGM4
GBE1ENST00000498468.1 linkn.258G>C non_coding_transcript_exon_variant Exon 3 of 4 3

Frequencies

GnomAD3 genomes
AF:
0.0000329
AC:
5
AN:
152082
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000655
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000588
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000208
AC:
5
AN:
240712
AF XY:
0.0000306
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000272
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000207
AC:
30
AN:
1446064
Hom.:
0
Cov.:
27
AF XY:
0.0000236
AC XY:
17
AN XY:
719216
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
32784
American (AMR)
AF:
0.00
AC:
0
AN:
43268
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25980
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39178
South Asian (SAS)
AF:
0.0000359
AC:
3
AN:
83488
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53362
Middle Eastern (MID)
AF:
0.000174
AC:
1
AN:
5740
European-Non Finnish (NFE)
AF:
0.0000218
AC:
24
AN:
1102382
Other (OTH)
AF:
0.0000334
AC:
2
AN:
59882
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.462
Heterozygous variant carriers
0
3
5
8
10
13
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000329
AC:
5
AN:
152200
Hom.:
0
Cov.:
32
AF XY:
0.0000403
AC XY:
3
AN XY:
74424
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41518
American (AMR)
AF:
0.0000654
AC:
1
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5180
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10572
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000588
AC:
4
AN:
68028
Other (OTH)
AF:
0.00
AC:
0
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.485
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000264
ExAC
AF:
0.0000248
AC:
3
Asia WGS
AF:
0.000289
AC:
1
AN:
3476

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Glycogen storage disease, type IV Pathogenic:5
Jul 22, 2021
Genome-Nilou Lab
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 04, 2024
Baylor Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 14, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: GBE1 c.708G>C (p.Gln236His) results in a non-conservative amino acid change located in the catalytic domain (IPR006047) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.1e-05 in 240712 control chromosomes (i.e. 5 heterozygous carriers) in the gnomAD database. The variant, c.708G>C, has been reported in the literature in at least 3 compound heterozygous individuals affected with Glycogen Storage Disease, Type IV (Burrow_2006, Malfatti_2016, Ravenscroft_2021), and in two of these cases biochemical- or electron microscopy studies confirmed the diagnosis in patient derived samples (Burrow_2006, Malfatti_2016). These data indicate that the variant is likely associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -

Aug 12, 2022
MGZ Medical Genetics Center
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 05, 2023
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:curation

The p.Gln236His variant in GBE1 has been reported in 4 individuals with glycogen storage disease type IV (GSD IV) (PMID: 16528737, 27546458, 33060286, 37598009) and has been identified in 0.003% (3/88322) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs137852892). Although this variant has been seen in the general population in a heterozygous state, its frequency is low enough to be consistent with a recessive carrier frequency. Of the 4 affected individuals, 2 were compound heterozygotes that carried a reported pathogenic variant in trans or with unknown phase which increases the likelihood that the p.Gln236His variant is pathogenic (VariationID: 208584; PMID: 33060286, 37598009). This variant has also been reported in ClinVar (Variation ID#: 2790) and has been interpreted as pathogenic by OMIM and Invitae, and likely pathogenic by Nilou-Genome Lab, Women's Health and Genetics/Laboratory Corporation of America (LabCorp), MGZ Medical Genetics Center, GeneDx, and PreventionGenetics (PreventionGenetics). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The phenotype of an individual compound heterozygous for this variant is highly specific for GSD IV based on strict biochemical investigations consistent with disease (PMID: 16528737). In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive GSD IV. ACMG/AMP Criteria applied: PP3, PM2_supporting, PM3_strong, PP4 (Richards 2015). -

Glycogen storage disease, type IV;C1849722:Adult polyglucosan body disease Pathogenic:1
May 23, 2024
Fulgent Genetics, Fulgent Genetics
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Glycogen storage disease due to glycogen branching enzyme deficiency, congenital neuromuscular form Pathogenic:1
Apr 15, 2006
OMIM
Significance:Pathogenic
Review Status:no assertion criteria provided
Collection Method:literature only

- -

GBE1-related disorder Pathogenic:1
Aug 29, 2023
PreventionGenetics, part of Exact Sciences
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The GBE1 c.708G>C variant is predicted to result in the amino acid substitution p.Gln236His. This variant has been reported in the compound heterozygous states in individuals with glycogen storage disease type 4 (Burrow et al. 2006. PubMed ID: 16528737; Malfatti et al. 2016. PubMed ID: 27546458; Table S2, Ravenscroft et al. 2020. PubMed ID: 33060286; Table 1, Magoulas et al. 2012. PubMed ID: 22305237). This variant is reported in 0.0070% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/3-81695617-C-G). This variant is interpreted as likely pathogenic. -

not provided Pathogenic:1
Apr 01, 2025
GeneDx
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 31589614, 16528737, 27546458, 38012812, 33060286, Miller2024[Abstract], 37598009) -

Glycogen storage disease, type IV;C1856301:Glycogen storage disease IV, classic hepatic Pathogenic:1
Oct 16, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces glutamine, which is neutral and polar, with histidine, which is basic and polar, at codon 236 of the GBE1 protein (p.Gln236His). This variant is present in population databases (rs137852892, gnomAD 0.007%). This missense change has been observed in individual(s) with GBE1-related conditions (PMID: 16528737, 27546458, 33060286). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 2790). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on GBE1 protein function. For these reasons, this variant has been classified as Pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.95
BayesDel_addAF
Pathogenic
0.37
D
BayesDel_noAF
Pathogenic
0.47
CADD
Benign
21
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.90
D;D
Eigen
Uncertain
0.29
Eigen_PC
Benign
0.045
FATHMM_MKL
Benign
0.42
N
LIST_S2
Pathogenic
0.99
D;D
M_CAP
Pathogenic
0.57
D
MetaRNN
Pathogenic
0.95
D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Uncertain
2.5
M;.
PhyloP100
0.61
PrimateAI
Uncertain
0.76
T
PROVEAN
Pathogenic
-4.6
D;D
REVEL
Pathogenic
0.83
Sift
Pathogenic
0.0
D;D
Sift4G
Pathogenic
0.0010
D;D
Polyphen
1.0
D;D
Vest4
0.99
MutPred
0.86
Gain of sheet (P = 0.1945);.;
MVP
0.97
MPC
0.23
ClinPred
0.98
D
GERP RS
1.6
Varity_R
0.97
gMVP
0.93
Mutation Taster
=5/95
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs137852892; hg19: chr3-81695617; API